Dr. Amir Faisal received his PhD in Cell Biology from Friedrich Miescher Institute for Biomedical Research/University of Basel, Switzerland in 2004. During his PhD he identified novel roles for Shc protein, an important adaptor downstream of tyrosine kinases, in insulin signalling and cytoskeletal reorganization. He received his first postdoctoral training (2004-2008) in Protein Phosphorylation Laboratory at London Research Institute where he discovered that another adaptor protein, MyD88, couples Protein Kinase C epsilon to Toll like receptors during innate immunity. From 2008 to 2014, he worked at Cancer Therapeutics Unit of Institute of Cancer Research in Sutton first as postdoctoral fellow and later as senior scientist. He played an important role in progression of several drug discovery projects, one of which resulted in discovery of a pre-clinical development candidate that will undergo phase I clinical trials in 2016. After joining LUMS in August 2014, he has been establishing a cancer therapeutics lab at SBASSE.\
| Title | Publication | Author | Year |
|---|---|---|---|
| Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors | Archiv der Pharmazie | 2023 | |
| Design, Synthesis, and Biological Evaluation of SSE1806, a Microtubule Destabilizer That Overcomes Multidrug Resistance | ACS Medicinal Chemistry Letters | 2023 | |
| Chemical Synthesis of Selenium-containing Peptides | Mini-Reviews in Medicinal Chemistry | 2023 | |
| Spontaneous NETosis in diabetes: A role of hyperglycemia mediated ROS and autophagy | Frontiers in Medicine | 2023 | |
| Selenium-containing Peptides and their Biological Applications | Current Medicinal Chemistry | 2022 | |
| Synthesis and Characterization of Griseofulvin Derivatives as Microtubule-Stabilizing Agents | ChemistrySelect | 2022 | |
| Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors | Frontiers in Chemistry | 2022 | |
| Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors | Journal of Natural Products | 2022 | |
| Synthesis and Evaluation of Novel Carboxamides Capable of Causing Centrosome Declustering and Apoptosis in Breast Cancer Cells | ChemistrySelect | 2022 | |
| Reduction-Sensitive Dextran-Paclitaxel Polymer-Drug Conjugate: Synthesis, Self-Assembly into Nanoparticles, and in Vitro Anticancer Efficacy | Bioconjugate Chemistry | 2021 | |
| Polycomb Requires Chaperonin Containing TCP-1 Subunit 7 for Maintaining Gene Silencing in Drosophila | Frontiers in Cell and Developmental Biology | 2021 | |
| CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells | British Journal of Cancer | 2021 | |
| A Personalized Therapeutics Approach Using an In Silico Drosophila Patient Model Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal Cancer | Frontiers in Oncology | 2021 | |
| Synthesis of diosgenin conjugated gold nanoparticles using algal extract of Dictyosphaerium sp. and in-vitro application of their antiproliferative activities | Materials Today Communications | 2021 | |
| Glyceryl Monostearate Based Solid Lipid Nanoparticles for Controlled Delivery of Docetaxel | Current Drug Delivery | 2021 | |
| Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors | Journal of Natural Products | 2020 | |
| Colon specific enzyme responsive oligoester crosslinked dextran nanoparticles for controlled release of 5-fluorouracil | International Journal of Pharmaceutics | 2020 | |
| Transcriptomic analysis reveals differential gene expression, alternative splicing, and novel exons during mouse trophoblast stem cell differentiation | Stem Cell Research and Therapy | 2020 | |
| A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)mediated multidrug resistance | PLoS ONE | 2020 | |
| Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 | Blood Advances | 2020 | |
| A facile and versatile route to functional poly(propylene) surfaces via UV-curable coatings | Reactive and Functional Polymers | 2019 | |
| Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species | European Journal of Pharmaceutical Sciences | 2019 | |
| Effect of Extraction Methodologies on Antioxidant Potential and Synergistic Anticancer Behavior of Leaf Extract of Polygonum amplexicaule Against HCT-116 Cells | Iranian Journal of Science and Technology, Transaction A: Science | 2019 | |
| Synthesis and evaluation of novel ??-substituted chalcones with potent anti-cancer activities and ability to overcome multidrug resistance | Bioorganic Chemistry | 2019 | |
| High proliferation rate and a compromised spindle assembly checkpoint confers sensitivity to the MPS1 inhibitor BOS172722 in triple-negative breast cancers | Molecular Cancer Therapeutics | 2019 |